Abbott Laboratories $ABT Stock Holdings Increased by Captrust Financial Advisors

Captrust Financial Advisors grew its position in shares of Abbott Laboratories (NYSE:ABT) by 1.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 466,721 shares of the healthcare product maker’s stock after buying an additional 6,296 shares during the period. Captrust Financial Advisors’ holdings in Abbott Laboratories were worth $62,513,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ABT. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the 3rd quarter valued at approximately $29,000. Guerra Advisors Inc bought a new stake in Abbott Laboratories during the third quarter valued at $31,000. Anfield Capital Management LLC raised its holdings in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares during the period. Delos Wealth Advisors LLC acquired a new stake in shares of Abbott Laboratories during the second quarter worth $32,000. Finally, Bridge Generations Wealth Management LLC bought a new position in shares of Abbott Laboratories in the 3rd quarter worth about $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the subject of a number of recent research reports. The Goldman Sachs Group lowered their price objective on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Daiwa Securities Group decreased their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Evercore lowered their target price on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Argus cut their price target on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Finally, Citigroup reduced their price objective on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research report on Wednesday, March 11th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $136.16.

Insiders Place Their Bets

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the transaction, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Price Performance

Shares of ABT opened at $108.41 on Thursday. Abbott Laboratories has a one year low of $105.27 and a one year high of $139.06. The stock’s fifty day moving average is $113.54 and its 200-day moving average is $123.39. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The firm has a market capitalization of $188.81 billion, a price-to-earnings ratio of 29.14, a price-to-earnings-growth ratio of 1.76 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.